REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs IR 103 (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms RAISE
- Sponsors Immune Response BioPharma
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
- 22 Feb 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019 as reported by ClinicalTrials.gov record.